Denna sida på svenska
Loading profile information...

About me

Tobias Nordström is a clinically active urologist, focusing on the detection and treatment of malignancies in the prostate and kidney, as well as treating general urological conditions. He started practicing urology 2007 and have achieved degrees in General Surgery and Urology at Danderyds Hospital. He was awarded Fellow of the European Board of Urology (FEBU) in 2015. 

Tobias Nordström defended the thesis "Predicting Prostate Cancer- on the use of biomarkers in Prostate Cancer Diagnostics" in January 2015 after which he undertook international postdoctoral studies at University of California, San Francisco.

He combines clinical surgical practice at Danderyds Hospital with independent research at Karolinska Institutet. Centrepieces of his work includes leading  guidelines development and implementing improvements in clinical care such as targeted prostate biopsies and imaging.


2015-  Postdoc (Dpt Medical Epidemiology and Biostatistics, KI)

2015-  Clinical Urologist (Danderyds Hospital)

2015   Fellow of the European Board of Urology (FEBU)

2015   Postdoc (University of California, San Francisco)

2015   Ph.D. (Dpt Clinical Sciences at Danderyds Hospital, KI)

2013   General Surgeon (Danderyds Hospital)

2007   M.D.  (KI)

Research description

The over-arching aim of Tobias Nordströms research is to improve detection and treatment of prostate cancer. Current work emanates from different perspectives, resulting in several different projects. 

An improved diagnostic chain for prostate cancer
The hypothesis is that combining improved blood-based testing and imaging techniques will improve detection of prostate cancer. Tobias Nordström is principal investigator for the STHLM3MR-projects, aiming to investigate the value of Magnetic Resonance Imaging (MRI) in prostate cancer detection. The STHLM3MR Main study is a large randomized study, exploring a combination of using the STHLM3 test and targeted biopsies using MRI/Fusion tehnique. 

Traditional tools for prostate cancer detection
Several tools are already availiable to aid decisions in prostate cancer diagnostics, but evidence are often scarce. Using contemporary, high-quality data, dr Nordström systematically explore the value of traditionally used markers of prostate cancer risk such as prostate volume, voiding symtoms, repeated blood-testing et cetera.

Current diagnostics of prostate cancer
Using the populationbased cohort STHLM0, dr Nordström work with describing how detection of prostate cancer is currently being performed. For example, he described current patterns of PSA-testing, use of prostate biopsies and frequency of biopsy-related complications.

Academic honours, awards and prizes

2017  European Meeting on Urinary Cancers (EMUC) - Best poster award

2017  Astellas Cutting Edge Award

2016  European Association of Urology (EAU) Annual Meeting - Best poster award

2014  StratCan International Postdoc award

2011  StratCan Ph.D. award

2011  Research Resident


Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
Australian Prostate Cancer Bioresource (apcb), Prostate Cancer Genome-wide Association Study Of Uncommon Susceptibility Loci (pegasus), Cancer Of The Prostate In Sweden (caps), Practical (prostate Cancer Association Group To Investigate Cancer-associated Alterations In The Genome) Consortium, Breast And Prostate Cancer Cohort Consortium (bpc3), Canary Pass Investigators, et al
Nature genetics 2018;50(7):928-936

Balancing Overdiagnosis and Early Detection of Prostate Cancer using the Stockholm-3 Model
Nordström T, Grönberg H, Adolfsson J, Egevad L, Aly M, Eklund M
European urology focus 2018;4(3):385-387

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesis
Mayrhofer M, De Laere B, Whitington T, Van Oyen P, Ghysel C, Ampe J, et al
Genome medicine 2018;10(1):85-

Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants
Practical (prostate Cancer Association Group To Investigate Cancer-associated Alterations In The Genome) Consortium, Dadaev T, Saunders Ej, Newcombe Pj, Anokian E, Leongamornlert Da, et al
Nature communications 2018;9(1):2256-

[Improved prostate cancer diagnostics with a struc-tured pathway including the Stockholm3 test and MRI--targeted biopsies - experiences from Capio S:t Göran Prostate Cancer Center]
Bergman M, Hjälm Ericsson M, Jäderling F, Meurling E, Thorstensson A, Nordström T, et al
Lakartidningen 2018;115():-

Poor Follow-up After Elevated Prostate-specific Antigen Tests: A Population-based Cohort Study
Aly M, Clements M, Weibull Ce, Nordström T, Näslund E, Adolfsson J, et al
European urology focus 2018;():-

Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging
Grönberg H, Eklund M, Picker W, Aly M, Jäderling F, Adolfsson J, et al
European urology 2018;74(6):722-728

Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer
Nordström T, Akre O, Aly M, Grönberg H, Eklund M
Prostate cancer and prostatic diseases 2018;21(1):57-63

Reply to Ola Bratt and Anna Öfverholm's Letter to the Editor re: Peter Ström, Tobias Nordström, Henrik Grönberg, Martin Eklund. The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential. Eur Urol. In press.
Eklund M, Ström P, Nordström T, Grönberg H
European urology 2018;74(1):e10-e11

Response to Walsh
Ström P, Lantz Aw, Grönberg H, Nordström T, Eklund M
Journal of the National Cancer Institute 2018;():-

Re: Tobias Nordström, Andrew Vickers, Melissa Assel, Hans Lilja, Henrik Grönberg, Martin Eklund. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. Eur Urol 2015;68:139-46
Vickers A, Nordström T, Assel M, Lilja H, Grönberg H, Eklund M
European urology 2018;74(2):e35-e36

Risk of Prostate Cancer in Men Treated With 5α-Reductase Inhibitors-A Large Population-Based Prospective Study
Wallerstedt A, Strom P, Gronberg H, Nordstrom T, Eklund M
Journal of the National Cancer Institute 2018;110(11):1216-1221

Streptococcal M protein promotes IL-10 production by cGAS-independent activation of the STING signaling pathway
Movert E, Lienard J, Valfridsson C, Nordström T, Johansson-lindbom B, Carlsson F
PLoS pathogens 2018;14(3):e1006969-

The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort
Möller A, Olsson H, Grönberg H, Eklund M, Aly M, Nordström T
Prostate cancer and prostatic diseases 2018;():-

The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential
Ström P, Nordström T, Aly M, Egevad L, Grönberg H, Eklund M
European urology 2018;74(2):204-210

Towards Next-generation Urine-based Prostate Cancer Risk Stratification
Nordström T, Lindberg J, Eklund M
European urology 2018;74(6):739-740

Detection of Prostate Cancer Using a Multistep Approach with Prostate-specific Antigen, the Stockholm 3 Test, and Targeted Biopsies: The STHLM3 MRI Project
Nordström T, Picker W, Aly M, Jäderling F, Adolfsson J, Ström P, et al
European urology focus 2017;3(6):526-528

Effects of increasing the PSA cutoff to perform additional biomarker tests before prostate biopsy
Nordström T, Adolfsson J, Grönberg H, Eklund M
BMC urology 2017;17(1):92-

Future directions in prostate cancer testing: a comment upon results from the prospective population-based diagnostic STHLM3 study-Grönberg H et al. Lancet Oncology. 2015 Nov 9; doi:10.1016/S1470-2045(15)00361-7
Nordström T, Eklund M, Grönberg H
World journal of urology 2017;35(6):895-896

Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer
Hoffmann Tj, Passarelli Mn, Graff Re, Emami Nc, Sakoda Lc, Jorgenson E, et al
Nature communications 2017;8():14248-

A population-based study on the association between educational length, prostate-specific antigen testing and use of prostate biopsies
Nordström T, Bratt O, Örtegren J, Aly M, Adolfsson J, Grönberg H
Scandinavian journal of urology 2016;50(2):104-9

Associations between circulating carotenoids, genomic instability and the risk of high-grade prostate cancer
Nordström T, Van Blarigan El, Ngo V, Roy R, Weinberg V, Song X, et al
The Prostate 2016;76(4):339-48

Repeat Prostate-Specific Antigen Tests Before Prostate Biopsy Decisions
Nordström T, Adolfsson J, Grönberg H, Eklund M
Journal of the National Cancer Institute 2016;108(12):-

The STHLM3 prostate cancer diagnostic study: calibration, clarification, and comments
Eklund M, Grönberg H, Nordström T
Nature reviews. Clinical oncology 2016;13(6):-

The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50-69 yr Compared with Current Prostate Cancer Testing
Eklund M, Nordström T, Aly M, Adolfsson J, Wiklund P, Brandberg Y, et al
European urology focus 2016;():-

Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer
Nordström T, Vickers A, Assel M, Lilja H, Grönberg H, Eklund M
European urology 2015;68(1):139-46

Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study
Grönberg H, Adolfsson J, Aly M, Nordström T, Wiklund P, Brandberg Y, et al
The Lancet. Oncology 2015;16(16):1667-76

Rapid increase in multidrug-resistant enteric bacilli blood stream infection after prostate biopsy - A 10-year population-based cohort study
Aly M, Dyrdak R, Nordström T, Jalal S, Weibull Ce, Giske Cg, et al
The Prostate 2015;75(9):947-56

The risk of prostate cancer for men on aspirin, statin or antidiabetic medications
Nordström T, Clements M, Karlsson R, Adolfsson J, Grönberg H
European journal of cancer (Oxford, England : 1990) 2015;51(6):725-33

A genetic score can identify men at high risk for prostate cancer among men with prostate-specific antigen of 1-3 ng/ml
Nordström T, Aly M, Eklund M, Egevad L, Grönberg H
European urology 2014;65(6):1184-90

Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003-2011
Nordström T, Aly M, Clements Ms, Weibull Ce, Adolfsson J, Grönberg H
European urology 2013;63(3):419-25

Reply from Authors re: Goutham Vemana, Gerald L. Andriole. Bad Habits May Be Hard to Break. Eur Urol 2013;63:426-7: Changing Habits
Nordström T, Clements Ms, Adolfsson J, Grönberg H
European urology 2013;63(3):427-

Show all publications